The medical merry-go-round: drugs for 1998 are new but not novel.
Gilden
D
D
D000225:Adenine / Q000009:adverse effects / Q000627:therapeutic use*; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines; D002219:Carbamates; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019258:Saquinavir / Q000008:administration & dosage* / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load; D000099227:Abacavir
D000225:Adenine; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019258:Saquinavir; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir; C098320:efavirenz